



mutations have a
tight grip
on pancreatic
adenocarcinoma^{1,2}



Learn more at
ExpectRAS.com

RAS=rat sarcoma virus.

RAS is a key oncogenic driver of PDAC^{1,2}

RAS plays a pivotal role in PDAC and is an important therapeutic target²

Over 90% of patients with PDAC have tumors carrying a RAS mutation¹

~85% of PDAC has
a KRAS mutation at codon G12¹

Prevalence of selected KRAS variants in PDAC¹

G12D	G12V	G12R	G12C
40%	29%	15%	<2%

When PDAC presents, expect RAS¹



Discover how
RAS impacts PDAC at
ExpectRAS.com

KRAS=Kirsten rat sarcoma virus; PDAC=pancreatic adenocarcinoma.

References: 1. Lee JK, Sivakumar S, Schrock AB, et al. Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors. *NPJ Precis Oncol.* 2022;6(1):91. doi:10.1038/s41698-022-00334-z 2. Gurreri E, Genovese G, Perelli L, et al. KRAS-dependency in pancreatic ductal adenocarcinoma: mechanisms of escaping in resistance to KRAS inhibitors and perspectives of therapy. *Int J Mol Sci.* 2023;24(11):9313. doi:10.3390/ijms24119313

